Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry. - Barron's
1. MRNA stock dropped 4.36% amid vaccine sales doubts. 2. Goldman Sachs cut MRNA rating to Neutral, target price to $51. 3. Demand for Covid-19 vaccines has significantly declined since 2022. 4. Analysts project lower end of expected revenue for MRNA's respiratory vaccines. 5. Partnerships in new therapies may provide medium-term growth opportunities.